Fox Chase Cancer Center Researchers: New Drug May Be Used to Treat Women with Ovarian Cancer
ANAHEIM, CALIF. (April 20, 2005) -- A new drug, RAD001, has been shown to stop the growth and movement of certain ovarian cancer cells, according to scientists at Fox Chase Cancer Center in Philadelphia. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, Calif.
A large percentage of human cancers have high activity levels of an enzyme known as AKT. This enzyme controls a number of cell functions, including cell size, division and response to chemotherapy.
"The AKT signaling pathway is overly active in a wide variety of different cancers, including ovarian carcinoma, so we and others think that this pathway is an attractive target for cancer treatment at the molecular level," said Joseph Testa, PhD, director of the Human Genetics Program at Fox Chase. "However, because the AKT pathway is involved in so many cell processes, many of them beneficial, we were looking to control some of the proteins downstream from AKT so we didn't inhibit the good processes."
RAD001 is a derivative of rapamycin, a drug used as an immunosuppressant. RAD001 targets an enzyme known as mTOR (mammalian target of rapamycin). In mice injected with human ovarian cancer cells with high AKT activity, the researchers found that RAD001 arrested the cells so they couldn't divide (reproduce) or move to another location in the body (metastasize). The drug also reduced the cancer cells' ability to make blood vessels to nourish themselves (angiogenesis). In cancer cells with low levels of AKT activity, RAD001 had minimal effect.
Testa speculates that after being immobilized by RAD001, ovarian cancer cells could be vulnerable to chemotherapy that would kill the cells while their reproductive properties are weakened.
"Ovarian cancer is the leading cause of gynecologic cancer deaths," Testa said. "It usually isn't detected until it's quite advanced and is hard to treat. This is one drug that is well-tolerated and could be useful in ovarian cancer treatment."
Along with Testa, study authors are Fox Chase postdoctoral associate Seiji Mabuchi, MD, PhD. and staff scientist Deborah Altomare, PhD.
96th Annual Meeting of the American Association for Cancer Research
Poster Session: Targeting Signaling Pathways 2
Exhibit Hall B-D, Anaheim Convention Center
Abstract #5971, Board #10:
Antitumor Efficacy of Rapamycin Derivative RAD001 in Human Ovarian Cancer
To be presented Wednesday, April 20, 2005, from 8 a.m. to 12 noon
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy6 Moore at 215-728-2700.